Testing effectiveness (Phase 2)Ended earlyNCT03781414
What this trial is testing
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
Who this might be right for
Liver Transplant Rejection
Novartis Pharmaceuticals 129